Business Context and Reporting Period
Company: McKesson Corporation
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and nine months ended December 31, 2004 (Fiscal Year 2005)
Business Overview: McKesson operates in three primary segments: Pharmaceutical Solutions (distribution of drugs and health products), Medical-Surgical Solutions (distribution of medical supplies), and Provider Technologies (healthcare software and automation). The company reorganized its reporting segments effective April 1, 2004.
Key Financial Metrics
| Metric | Quarter Ended Dec 31, 2004 | Nine Months Ended Dec 31, 2004 |
|---|---|---|
| Revenues | $20,781.9 million | $59,902.8 million |
| Gross Profit | $840.6 million | $2,427.6 million |
| Gross Margin | 4.04% | 4.05% |
| Operating Income (Loss) | $(965.4) million | $(575.8) million |
| Net Income (Loss) | $(665.4) million | $(415.7) million |
| Diluted EPS | $(2.26) | $(1.42) |
| Cash from Operations (9mo) | $534.1 million | |
| Working Capital | $3,261.3 million | |
| Total Debt (Current + Long-Term) | $1,461.7 million | |
| Cash and Equivalents | $1,032.9 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 14% for the quarter and 16% for the nine months compared to the prior year, driven primarily by the Pharmaceutical Solutions segment (94% of total revenue) and growth in Provider Technologies.
- Profitability Decline: The company reported a net loss of $665.4 million for the quarter and $415.7 million for the nine months, a significant reversal from net income of $120.2 million and $432.3 million in the comparable 2003 periods.
- Securities Litigation Charge: The primary driver of the loss was a pre-tax charge of $1.2 billion ($810 million after-tax) recorded in the third quarter of 2005 to settle the "Securities Litigation" regarding accounting improprieties at a former subsidiary (HBOC). This charge consisted of $960 million for the consolidated class action and $240 million for other related proceedings.
- Operating Expenses: Total operating expenses surged 216% for the quarter and 78% for the nine months due to the litigation charge. Excluding this charge, operating expenses as a percentage of revenue decreased due to productivity improvements.
- Cash Flow: Operating cash flow improved significantly to $534.1 million for the nine months ended Dec 31, 2004, compared to a utilization of $242.1 million in the prior year, aided by improved receivables collections and inventory management.
Guidance, Outlook, Risks, and Unusual Items
- Unusual Items:
- Securities Litigation: A $1.2 billion pre-tax charge was recorded. The company expects to pay $960 million in cash for the consolidated settlement, subject to court approval. A $240 million reserve was established for other litigation.
- Antitrust Settlements: The Pharmaceutical Solutions segment received $41.2 million in cash proceeds from an antitrust class action settlement in the first quarter of 2005, recorded as a reduction to cost of sales.
- Contract Losses: A $20 million provision was recorded in the third quarter for contract losses in the Provider Technologies segment, partially offset by a $15.2 million reduction in the fourth quarter.
- Outlook and Management Commentary:
- Management expects the new Department of Veterans Affairs contract to generate over $3.5 billion in annual revenues.
- The company anticipates completing negotiations with the UK National Health Services (NHS) regarding a delayed contract by the end of fiscal 2005; failure to agree could result in material losses.
- Management believes the company has sufficient liquidity to finance the litigation settlement when due.
- Risks and Contingencies:
- Legal: Uncertainty remains regarding the final tax deductibility of the litigation settlement; an $85 million tax reserve has been established.
- Operational: Risks include the integration of the Moore Medical Corp. (MMC) acquisition, potential losses from the NHS contract, and general healthcare market consolidation.
- Financial: Exposure to foreign currency fluctuations and changes in manufacturer pricing policies.
Investor Verification Checklist
- Litigation Settlement Status: Verify the final court approval of the $960 million securities litigation settlement and the actual cash outflow timing.
- Tax Deductibility: Monitor the resolution of the $85 million tax reserve regarding the deductibility of the litigation settlement.
- NHS Contract Resolution: Track the outcome of negotiations with the UK National Health Services to assess potential impairment of the $94 million investment or additional losses.
- Working Capital Trends: Review future quarters for the impact of the new Veterans Affairs contract on receivables and inventory levels.
- Segment Margins: Analyze the sustainability of gross margin improvements in the Pharmaceutical Solutions segment given competitive pricing pressures and changes in vendor incentives.